MetaCap

Bausch Health Companies Inc. (BHC)

NYSE: BHCHealth CareBiotechnology: Pharmaceutical PreparationsUSD

8.22-0.34 (-3.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

BHC stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.26
Ex-dividend date
Nov 10, 2010
52-week range
4.33 – 9.04
Day range
8.12 – 8.55
Volume / Avg
3.84M / 3.16M
Beta
—

52-week range

$4.33$9.04

BHC stock today

Shares of Bausch Health Companies (BHC) finished lower on Nov 20 at $8.22, a drop of 3.97% or $0.34 per share, versus the S&P 500's 3.70% decline. Shares are 9.1% below their 52-week high of $9.04, set on Oct 29, 2026 and 89.8% above the 52-week low of $4.33, near the top of the past year's range. BHC is up 18.3% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 36.3%.

Bausch Health Companies has posted a net loss over the last twelve months (EPS of -$2.26), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Bausch Health Companies

Company profile

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company. It operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Thomas J. Appio
Headquarters
Laval, QC
Employees
20,300

Financial highlights

Full financials

In fiscal 2025, Bausch Health Companies generated $10.27 billion in revenue, up 6.7% from fiscal 2024, its 3rd consecutive year of revenue growth. Net income was $157.0 million, for a net margin of 1.5% versus a median of -6.8% in the prior 5 years. Operating margin was 17.7%.

Bausch Health Companies annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$10.27B$9.63B$8.76B$8.12B$8.43B
Growth+6.66%+9.91%+7.79%-3.68%+5.07%
Net income$157.00M$-46.00M$-592.00M$-225.00M$-948.00M
EPS (diluted)$0.42$-0.13$-1.62$-0.62$-2.64

Analyst forecast

Forecast

Consensus (7 analysts)

hold

Avg. price target

$8.40+2.19%

  • Strong buy 0
  • Buy 0
  • Hold 7
  • Sell 0
  • Strong sell 0

Target range

Low $7.00High $10.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 28, 2026
EPS actual vs est.
$1.16 vs $1.08
Surprise
+7.41%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$1.00
Ex-dividend date
Nov 10, 2010

BHC news

All BHC news

Bausch Health Companies peers

Health Care sector
BHC peer companies
CompanyPrice% ChgMarket capCompare
XERSXeris Biopharma Holdings Inc.16.97+2.11%$3.10Bvs BHC
VKTXViking Therapeutics Inc.24.77-4.14%$3.16Bvs BHC
ABCLAbCellera Biologics Inc.9.69-7.45%$3.16Bvs BHC
LEGNLegend Biotech Corporation ADR15.25-5.28%$2.96Bvs BHC
ACADACADIA Pharmaceuticals Inc.17.11-2.73%$2.96Bvs BHC
DYNDyne Therapeutics Inc.15.50-3.31%$2.90Bvs BHC
TLXTelix Pharmaceuticals Limited ADR8.37-3.90%$2.84Bvs BHC
ARQTArcutis Biotherapeutics Inc.26.36-2.98%$3.33Bvs BHC

Indexes, lists and sector

Bausch Health Companies stock FAQ

What is Bausch Health Companies's stock price today?

BHC last traded at $8.22 as of Nov 20, 4:00 PM EST, down 3.97% on the day. Prices are delayed at least 15 minutes.

Does Bausch Health Companies pay a dividend?

Yes. Bausch Health Companies pays $0.00 per share annually. The most recent dividend of $1.00 had an ex-dividend date of Nov 10, 2010.

Who is Bausch Health Companies's CEO?

Mr. Thomas J. Appio is the chief executive officer of Bausch Health Companies Inc., which has about 20,300 employees.

Has BHC ever split its stock?

Yes. The most recent BHC stock split was a 2-for-1 split on Oct 16, 2000, one of 3 splits on record.

What is the BHC 52-week high?

The 52-week high for BHC is $9.04 and the 52-week low is $4.33. The stock is currently 9.1% below its high.

Compare BHC